Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

作者
Yu Hu,Renchi Yang,Xiaofan Liu,Heng Mei,Hu Zhou,Shujie Wang,Ruibin Huang,Yi Wang,Xin Du,Jing Sun,Zeping Zhou,Zhenyu Yan,Wen-Ming Chen,Wei Wang,Qingchi Liu,Qingshu Zeng,Yuping Gong,Jie Yin,Xuliang Shen,Baodong Ye
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 843-843
标识
DOI:10.1182/blood-2025-843
摘要

Abstract Introduction Sovleplenib, a novel spleen tyrosine kinase (SYK) inhibitor, demonstrated promising safety and efficacy in primary immune thrombocytopenia (ITP) patients (pts) in phase 1b/2 trials, with these favorable outcomes subsequently confirmed in double-blinded phase 3 ESLIM-01 study (NCT05029635). This final analysis of ESLIM-01 sought to report the long-term efficacy and safety of sovleplenib in adult pts with ITP. Methods In ESLIM-01, adult pts with chronic primary ITP were randomized 2:1 to receive oral sovleplenib 300 mg once daily or placebo for 24 weeks. Pts who completed 24 weeks double-blinded treatment or demonstrating non-response within initial 12 weeks in ESLIM-01 were enrolled in an open-label extension sub-study (sovleplenib 300 mg once daily). Long-term efficacy and safety evaluations encompassed all participants who received ≥1 dose of sovleplenib (all Sov group), including placebo-crossover subjects (P-Sov group). Main efficacy endpoints included durable response in long-term follow up (PLT ≥ 50×10/L at ≥ 2 of 3 any 12-week consecutive protocol-defined visits after receiving sovleplenib for 12 weeks, not impacted by rescue treatment) and complete response rate (the proportion of pts with at least one PLT ≥100×10⁹/L under sovleplenib treatment, not impacted by rescue treatment). Results As of the March 31, 2025 data cutoff, 179 pts (all Sov) received at least one dose of sovleplenib treatment. Of these, 126 pts received sovleplenib initially during double-blinded period, while 53 pts (P-Sov) switched from placebo. The two groups were comparable in terms of baseline characteristics. At baseline, the median age in all Sov group was 43.0 years (range, 18.0-72.0) and 41.0 years (range, 18.0-69.0) in P-Sov group. The median platelet counts at baseline were 12.0×10⁹/L in both the all Sov and P-Sov groups. The proportion of pts who received concomitant anti-ITP medication at baseline was 30.7% in all Sov group and 26.4% in P-Sov group. 110 pts (61.5%) in all Sov group and 34 pts (64.2%) in P-Sov group achieved durable response in long-term follow up, respectively. The complete response rate was 67.6% in all Sov group and 68.0% in P-Sov group. The maximum continuous duration of PLT ≥ 50×10⁹/L (or≥ 30×10⁹/L) was 25.9 weeks (or 37.0 weeks) in all Sov group, and 20.4 weeks (or 35.6 weeks) in P-Sov group. Cumulative duration of PLT ≥ 50×10⁹/L (or≥ 30×10⁹/L) in all Sov group was 66.7 weeks (or 77.0 weeks) and 50.4 weeks (or 68.1 weeks) in P-Sov group. 16 pts (8.9%) reduced/discontinued concomitant anti-ITP medication in all Sov group and 5 pts (9.4%) in P-Sov group. The median duration (min, max) of exposure was 604.0 days (14.0, 1093.0) in all Sov group and 617.0 days (14.0, 1093.0) in P-Sov group. Treatment-related adverse events (TRAEs) were reported in 87.2% (156/179) of patients in all Sov group and 88.7% (47/53) in P-Sov group. The majority of AEs were Grade 1-2. The long-term safety profiles were consistent with those in sovleplenib group in ESLIM-01. The most common (>2.0%) TRAEs of grade ≥3 in all Sov group were alanine aminotransferase increased (4 [2.2%]), neutrophil count decreased (5 [2.8%]); for P-Sov group, it was aspartate aminotransferase increased (2 [3.8%]). Major bleeding events (ISTH criteria) occurred in 2.2% of all Sov group and 3.8% of P-Sov group. The study had no mortality events. Conclusions Long-term treatment with sovleplenib demonstrated clinically meaningful and sustained platelet responses in adult pts with ITP in China, while maintaining a tolerable safety profile. These findings support sovleplenib as a promising therapeutic option for adult pts with chronic primary ITP.Keywords: SYK, Immune thrombocytopenia (ITP), Sovleplenib, ESLIM-01

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Daisy完成签到 ,获得积分10
1秒前
执着的天使完成签到 ,获得积分10
2秒前
生动的乐曲完成签到,获得积分10
2秒前
ChengYonghui完成签到,获得积分10
3秒前
火星上蜜粉完成签到,获得积分10
4秒前
树妖三三完成签到,获得积分10
5秒前
5秒前
crab完成签到,获得积分10
6秒前
厉奕欣完成签到 ,获得积分10
7秒前
QwQ完成签到 ,获得积分10
10秒前
SSY发布了新的文献求助10
10秒前
Wei发布了新的文献求助20
13秒前
Orange的应助被酷酷的怀莲采纳,获得10
17秒前
19秒前
xfy的应助被科研通管家采纳,获得10
19秒前
淡然雁梅完成签到 ,获得积分10
20秒前
ri_290完成签到,获得积分10
21秒前
21秒前
xzcx完成签到 ,获得积分10
21秒前
方方完成签到,获得积分10
22秒前
心如止水完成签到,获得积分10
24秒前
SCINEXUS完成签到,获得积分0
24秒前
怡然绯完成签到 ,获得积分10
25秒前
书生完成签到,获得积分10
29秒前
张倾情完成签到,获得积分10
29秒前
翻斗花园吴靓靓完成签到 ,获得积分10
30秒前
Anatee完成签到,获得积分10
30秒前
忧伤的平安完成签到,获得积分10
33秒前
情怀的应助被帆320采纳,获得10
34秒前
34秒前
kevin完成签到,获得积分10
34秒前
Wei完成签到,获得积分10
38秒前
王kk完成签到 ,获得积分10
39秒前
海风完成签到,获得积分10
40秒前
辛辛那提完成签到,获得积分10
42秒前
乐无忧完成签到 ,获得积分10
42秒前
炳灿完成签到 ,获得积分10
45秒前
Skywalk满天星完成签到,获得积分10
45秒前
烂漫向梦完成签到,获得积分10
46秒前
47秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166556
求助须知:如何正确求助?哪些是违规求助? 9559576
关于积分的说明 21750809
捐赠科研通 7757392
什么是DOI,文献DOI怎么找? 3429167
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923